- active not recruitingPHASE1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
This study is testing a new medicine called RG6496 for Huntington's disease. Researchers want to see if it's safe, how the body handles it, and what effects it might have. This is the very first time it's being given to people.
Argentina · Australia · Canada - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomized, Placebo-controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects with Huntington’s Disease
This study is testing a new medicine, PTC518, for Huntington's Disease. Researchers want to see if it's safe, how well it works, and what dose might be best. Participants will receive either the medicine or a dummy pill.
Germany · Spain · Italy - recruitingPHASE1
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
This study is testing a new medicine, ALN-HTT02, for Huntington's disease. Researchers want to see if it's safe and how it works in the body. It's a first-step study, comparing the new medicine to a dummy treatment (placebo) in adults aged 25-70.
Canada · Germany · United Kingdom - recruiting
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
This study, HDClarity, aims to gather fluid samples from people with Huntington's disease to find better ways to treat it. By studying blood and spinal fluid, researchers hope to understand the disease better and develop new medicines.
United States · Canada · France - recruiting
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is a long-term study collecting information and samples from people with or at risk of Huntington's disease (HD), and their families. This helps researchers worldwide better understand HD, find new ways to treat it, and design better clinical trials for the future.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients
This study is testing a new medicine called MBF-015 for Huntington's disease. Researchers want to see if it's safe, how the body handles it, and if it could help. It's a small, early-stage study focusing on safety over 28 days.
Spain